{"id":8555,"date":"2020-02-20T17:17:31","date_gmt":"2020-02-20T11:47:31","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=8555"},"modified":"2023-02-10T12:12:04","modified_gmt":"2023-02-10T06:42:04","slug":"recent-pharma-happenings-for-incyte-neotx-five-prime","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-incyte-neotx-five-prime","title":{"rendered":"Incyte meets endpoint in second atopic dermatitis trial; NeoTX lands USD 45 M series C; Five Prime Therapeutics\u2019 pancreatic cancer a bust"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\" id=\"h-incyte-meets-endpoint-in-the-second-pivotal-atopic-dermatitis-clinical-trial\"><strong>Incyte meets endpoint in the second pivotal atopic dermatitis clinical trial<\/strong><\/h2>\n\n\n\n<p>A second phase 3 trial of Incyte\u2019s ruxolitinib cream in <a href=\"https:\/\/www.delveinsight.com\/report-store\/atopic-dermatitis-ad-market\">atopic dermatitis<\/a> has hit its primary endpoint. The back-to-back pivotal successes irked Incyte to talk to regulators regarding upcoming of the JAK inhibitor to market.<\/p>\n\n\n\n<p>Ruxolitinib is the small molecule JAK1\/2 inhibitor found in Jakafi, for <a href=\"https:\/\/www.delveinsight.com\/report-store\/myelofibrosis-mf-market\">myelofibrosis treatment<\/a> of Incyte. Incyte has placed itself to produce more cash from the molecule by positioning it as an atopic dermatitis treatment option for patients.<\/p>\n\n\n\n<p>Lately, Incyte has shown top-line data from the second phase 3 trial. The second trial also hit its primary endpoint, with more than 50% of patients on the higher dose of ruxolitinib reaching success on an investigator assessment when compared to 8% in the placebo group.<br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-neotx-therapeutics-lands-usd-45-million-series-c-for-combo-i-o-cancer-trials\"><strong>NeoTX Therapeutics<\/strong>&nbsp;<strong>lands USD 45 Million series C for combo I-O cancer trials<\/strong><\/h2>\n\n\n\n<p>NeoTX Therapeutics, a biopharmaceutical company developing <a href=\"https:\/\/www.delveinsight.com\/blog\/metastatic-pancreatic-cancer-market-size\">cancer <\/a>immunotherapies. The company has landed a boastful of USD 45 million third funding round as it is up for continuing work on its early-stage <a href=\"https:\/\/www.delveinsight.com\/blog\/non-small-cell-lung-cancer-market\">cancer <\/a>combo test and in-license new tech.<\/p>\n\n\n\n<p>NeoTX is leveraging its proprietary Selective T cell Redirection (STR) platform to develop new targeted anticancer immunotherapies.&nbsp;&nbsp;<\/p>\n\n\n\n<p>The Rehovot, Israel-based biotech is actively working on a Selective T cell Redirection (STR) platform for its <a href=\"https:\/\/www.delveinsight.com\/report-store\/gene-therapy-in-oncology-innovation-to-commercialization-competitive-landscape\">oncology <\/a>immunotherapies, and now its total funding draws to USD 60 million.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-a-combo-of-the-pancreatic-cancer-of-five-prime-therapeutics-with-opdivo-a-bust\"><strong>A combo of the pancreatic cancer of Five Prime Therapeutics with Opdivo a bust<\/strong><\/h2>\n\n\n\n<p>Five Prime Therapeutics, a clinical-stage biotechnology company, aimed at discovering and developing innovative therapeutics to improve the lives of patients with serious diseases.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/pancreatic-cancer-market\">Pancreatic cancer<\/a> is a severe disease to treat. Unfortunately, the combination of Five Prime Therapeutics\u2019 experimental CSF-1 receptor inhibitor cabiralizumab and Bristol-Myers Squibb\u2019s checkpoint inhibitor Opdivo, with and without chemotherapy did not display any fruitful benefit over standard of care chemotherapy in this randomized, controlled phase 2 trial.<br><\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/blog\/metastatic-pancreatic-cancer-market-size\">Pancreatic cancer<\/a> has one of the lowest success rates lately among the biopharma oncology trials and is often detected late in the disease, with a very high level of mortality.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Incyte meets endpoint in the second pivotal atopic dermatitis clinical trial A second phase 3 trial of Incyte\u2019s ruxolitinib cream in atopic dermatitis has hit its primary endpoint. The back-to-back pivotal successes irked Incyte to talk to regulators regarding upcoming of the JAK inhibitor to market. Ruxolitinib is the small molecule JAK1\/2 inhibitor found in [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8557,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":1,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[7478,18065,1107,349,18063,18064,431,449,639,5789],"industry":[17225],"therapeutic_areas":[17237,17228],"class_list":["post-8555","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-atopic-dermatitis","tag-five-prime-therapeutics","tag-incyte","tag-latest-pharma-news","tag-myelofibrosis-treatment","tag-neotx-therapeutics","tag-opdivo","tag-pancreatic-cancer","tag-pharma-news","tag-recent-pharma-news","industry-pharmaceutical","therapeutic_areas-dermatology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News Updates | Incyte, NeoTX, Five Prime Therapeutics<\/title>\n<meta name=\"description\" content=\"Incyte meets endpoint in second atopic dermatitis trial; NeoTX lands USD 45 M series C; Five Prime Therapeutics\u2019 pancreatic cancer a bust\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-incyte-neotx-five-prime\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News Updates | Incyte, NeoTX, Five Prime Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Incyte meets endpoint in second atopic dermatitis trial; NeoTX lands USD 45 M series C; Five Prime Therapeutics\u2019 pancreatic cancer a bust\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-incyte-neotx-five-prime\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-02-20T11:47:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-10T06:42:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/20170644\/pharma-news.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"768\" \/>\n\t<meta property=\"og:image:height\" content=\"480\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News Updates | Incyte, NeoTX, Five Prime Therapeutics","description":"Incyte meets endpoint in second atopic dermatitis trial; NeoTX lands USD 45 M series C; Five Prime Therapeutics\u2019 pancreatic cancer a bust","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-incyte-neotx-five-prime","og_locale":"en_US","og_type":"article","og_title":"Pharma News Updates | Incyte, NeoTX, Five Prime Therapeutics","og_description":"Incyte meets endpoint in second atopic dermatitis trial; NeoTX lands USD 45 M series C; Five Prime Therapeutics\u2019 pancreatic cancer a bust","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-incyte-neotx-five-prime","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-02-20T11:47:31+00:00","article_modified_time":"2023-02-10T06:42:04+00:00","og_image":[{"width":768,"height":480,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/20170644\/pharma-news.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-incyte-neotx-five-prime","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-incyte-neotx-five-prime","name":"Pharma News Updates | Incyte, NeoTX, Five Prime Therapeutics","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-incyte-neotx-five-prime#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-incyte-neotx-five-prime#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/20170644\/pharma-news.jpg","datePublished":"2020-02-20T11:47:31+00:00","dateModified":"2023-02-10T06:42:04+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Incyte meets endpoint in second atopic dermatitis trial; NeoTX lands USD 45 M series C; Five Prime Therapeutics\u2019 pancreatic cancer a bust","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-incyte-neotx-five-prime"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-incyte-neotx-five-prime#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/20170644\/pharma-news.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/20170644\/pharma-news.jpg","width":768,"height":480,"caption":"Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/02\/20170644\/pharma-news-300x188.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Atopic dermatitis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Five Prime Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Incyte<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Myelofibrosis Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NeoTX Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Opdivo<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pancreatic Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Atopic dermatitis<\/span>","<span class=\"advgb-post-tax-term\">Five Prime Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Incyte<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Myelofibrosis Treatment<\/span>","<span class=\"advgb-post-tax-term\">NeoTX Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Opdivo<\/span>","<span class=\"advgb-post-tax-term\">Pancreatic Cancer<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Feb 20, 2020","modified":"Updated on Feb 10, 2023"},"absolute_dates_time":{"created":"Posted on Feb 20, 2020 5:17 pm","modified":"Updated on Feb 10, 2023 12:12 pm"},"featured_img_caption":"Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8555","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=8555"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8555\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/8557"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=8555"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=8555"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=8555"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=8555"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=8555"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}